Skip to content

Remimazolam besylate on hemodynamics and postoperative rehabilitation of patients undergoing endovascular aneurysm repair

Remimazolam besylate on hemodynamics and postoperative rehabilitation of patients undergoing endovascular aneurysm repair

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042350
Enrollment
Unknown
Registered
2021-01-19
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Aortic Aneurysms

Interventions

GAR1 group:Remazolam group was induced at 6mg/kg/h and maintained at 1~2mg/kg/h.
GAR2 group:Remazolam group was induced at 12mg/kg/h and maintained at 1~2mg/kg/h
GAP group:Propofol group was induced at 2~2.5mg/kg, at 4~12mg/kg/h Maintenance
LA group:outine local infiltration anesthesia

Sponsors

Zhuhai People's Hospital Affiliated with Jinan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. AAA was diagnosed by CT, MRI or (and) ultrasound at the time of admission, evaluated by a specialist and met the criteria for elective EVAR surgery [3], and the hospital stay was >= 3 days (including the time before and after surgery); 2. 18 years old <= age <= 80 years old, American anesthesiologist classification ASA <= III; 3. Clearly understand the experimental process and voluntarily participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. People who are known to be allergic to benzodiazepines or have severe allergies and family history; 2. Long-term use of opioids, psychiatric sedatives or non-steroidal anti-inflammatory drugs; 3. Symptomatic ischemic heart disease (such as unstable angina), moderate or severe decompensated heart failure, severe heart valve disease, obvious abnormal heart rhythm; 4. History of symptomatic cerebrovascular disease; 5. Severe or extremely severe respiratory function decline (such as FEV1/FVC 170µmol/L) 7. Severe liver function decompensation (such as AST/ALT >= 2.5ULN, ALB < 2.0g/dL); 8. Past mental illness history; 9. The researcher thinks it is not suitable to participate in this clinical research.

Design outcomes

Primary

MeasureTime frame
MAP;BIS;CI;SVI;MOAA/S;NIH Stroke Scale;levels of GABA;levels of Ang II;levels of Ang1-7;levels of IL-6;levels of IL-10;MACI;30-day mortality;

Countries

China

Contacts

Public ContactLiang Gen-Qiang

Zhuhai People's Hospital Affiliated with Jinan University

jiuqingliang@126.com+86 13926935089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026